Company attributes
Other attributes
Frontier Medicines is a biopharmaceutical company developing chemoproteomics for drug discovery that is headquartered in San Francisco, California and was founded in 2018 by Chris Varma. Frontier Medicines combines machine learning, advanced computation, and pharmacological knowledge to discover new binding pockets on proteins and create new small molecule therapeutics.
The Frontier Medicines chemoproteomics platform has three main components. A database of temporary drug targetable pockets found on human proteins, a library of chemically distinct compounds augmented by machine learning algorithms to help discover high-quality drug candidates for targeting temporary protein pockets, and a novel approach for simulating protein degradation. The company claims their chemoproteomics platform allows them to develop drugs for proteins which were previously thought to be 'undruggable'.
On June 25, 2019 Frontier Medicines announced raising $67 million in series A funding from MPM Capital (lead investor), Deerfield (lead investor), Droia (lead investor), Ra Capital Management, and Data Collective DCVC. The company plans on using their series A funding to increase its research and development efforts, hire more employees, and refine its drug discovery and therapeutic development programs.
